Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Pieris Pharmaceuticals stock | $4.32

Learn how to easily invest in Pieris Pharmaceuticals stock.

Pieris Pharmaceuticals Inc is a biotechnology business based in the US. Pieris Pharmaceuticals shares (PIRS) are listed on the NASDAQ and all prices are listed in US Dollars. Pieris Pharmaceuticals employs 111 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Pieris Pharmaceuticals

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PIRS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Pieris Pharmaceuticals stock price (NASDAQ: PIRS)

Use our graph to track the performance of PIRS stocks over time.

Pieris Pharmaceuticals shares at a glance

Information last updated 2021-10-17.
Latest market close$4.32
52-week range$1.70 - $6.15
50-day moving average $5.25
200-day moving average $3.65
Wall St. target price$8.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.85

Buy Pieris Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Pieris Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Pieris Pharmaceuticals price performance over time

Historical closes compared with the close of $4.32 from 2021-10-22

1 week (2021-10-15) -4.21%
1 month (2021-09-24) -23.13%
3 months (2021-07-23) 28.19%
6 months (2021-04-23) 89.47%
1 year (2020-10-23) 92.00%
2 years (2019-10-23) 35.85%
3 years (2018-10-23) 4.78
5 years (2016-10-21) 166.67%

Pieris Pharmaceuticals financials

Revenue TTM $23.7 million
Gross profit TTM $-14,814,000
Return on assets TTM -21.64%
Return on equity TTM -103.55%
Profit margin -203.73%
Book value $0.70
Market capitalisation $300.9 million

TTM: trailing 12 months

Shorting Pieris Pharmaceuticals shares

There are currently 1.1 million Pieris Pharmaceuticals shares held short by investors – that's known as Pieris Pharmaceuticals's "short interest". This figure is 2.1% down from 1.1 million last month.

There are a few different ways that this level of interest in shorting Pieris Pharmaceuticals shares can be evaluated.

Pieris Pharmaceuticals's "short interest ratio" (SIR)

Pieris Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Pieris Pharmaceuticals shares currently shorted divided by the average quantity of Pieris Pharmaceuticals shares traded daily (recently around 2.0 million). Pieris Pharmaceuticals's SIR currently stands at 0.55. In other words for every 100,000 Pieris Pharmaceuticals shares traded daily on the market, roughly 550 shares are currently held short.

However Pieris Pharmaceuticals's short interest can also be evaluated against the total number of Pieris Pharmaceuticals shares, or, against the total number of tradable Pieris Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Pieris Pharmaceuticals's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Pieris Pharmaceuticals shares in existence, roughly 20 shares are currently held short) or 0.0201% of the tradable shares (for every 100,000 tradable Pieris Pharmaceuticals shares, roughly 20 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Pieris Pharmaceuticals.

Find out more about how you can short Pieris Pharmaceuticals stock.

Pieris Pharmaceuticals share dividends

We're not expecting Pieris Pharmaceuticals to pay a dividend over the next 12 months.

Have Pieris Pharmaceuticals's shares ever split?

Pieris Pharmaceuticals's shares were split on a 25:11 basis on 7 December 2014. So if you had owned 11 shares the day before before the split, the next day you'd have owned 25 shares. This wouldn't directly have changed the overall worth of your Pieris Pharmaceuticals shares – just the quantity. However, indirectly, the new 56% lower share price could have impacted the market appetite for Pieris Pharmaceuticals shares which in turn could have impacted Pieris Pharmaceuticals's share price.

Pieris Pharmaceuticals share price volatility

Over the last 12 months, Pieris Pharmaceuticals's shares have ranged in value from as little as $1.7 up to $6.15. A popular way to gauge a stock's volatility is its "beta".

PIRS.US volatility(beta: 1.2)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pieris Pharmaceuticals's is 1.2021. This would suggest that Pieris Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Pieris Pharmaceuticals overview

Pieris Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, discovers and develops anticalin protein-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; and lead immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-expressing solid tumors. The company also develops PRS-344, a bispecific anticalin-antibody fusion protein targeting 4-1BB and PD-L1 for immuno-oncology diseases; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc. ; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc.

Frequently asked questions

What percentage of Pieris Pharmaceuticals is owned by insiders or institutions?
Currently 11.007% of Pieris Pharmaceuticals shares are held by insiders and 47.696% by institutions.
How many people work for Pieris Pharmaceuticals?
Latest data suggests 111 work at Pieris Pharmaceuticals.
When does the fiscal year end for Pieris Pharmaceuticals?
Pieris Pharmaceuticals's fiscal year ends in December.
Where is Pieris Pharmaceuticals based?
Pieris Pharmaceuticals's address is: 255 State Street, Boston, MA, United States, 02109
What is Pieris Pharmaceuticals's ISIN number?
Pieris Pharmaceuticals's international securities identification number is: US7207951036
What is Pieris Pharmaceuticals's CUSIP number?
Pieris Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 720795103

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site